F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.
IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star.
António Parada, CEO at IONTAS, commented: “We are delighted with the progress of this molecule, the platform offered by F-star taps into the growing number of bispecific antibodies entering the clinic and we are proud to be part of this movement. We wish F-star every success with the clinical trial and hope this can be the foundation of an effective cancer treatment.”
